Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 2/20 | 0.73 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | SRC | P12931 | 2/20 | 0.68 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.68 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.68 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.68 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.68 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.68 |
| ▸ | LDHA | P00338 | 1/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.68 |
| ▸ | FBP1 | P09467 | 1/20 | 0.68 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.68 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18486637 | 0.88 | ADORA1 (0.67) | AHCYP2RY1ADORA1P2RY2SMN1; SMN2 | |
| SCHEMBL18486728 | 0.85 | RNASEL (0.65) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL16682237 | 0.84 | AHCY (1.00) | AHCYP2RY1ADORA1P2RY2SMN1; SMN2 | |
| SCHEMBL26807050 | 0.84 | AHCY (1.00) | AHCYP2RY1ADORA1P2RY2SMN1; SMN2 | |
| SCHEMBL15371600 | 0.84 | AHCY (1.00) | AHCYP2RY1ADORA1P2RY2SMN1; SMN2 | |
| SCHEMBL3522303 | 0.84 | RNASEL (0.67) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL10997946 | 0.84 | ADORA1 (0.76) | AHCYP2RY1ADORA1P2RY2SMN1; SMN2 | |
| SCHEMBL12963362 | 0.84 | ADORA1 (0.76) | AHCYP2RY1ADORA1P2RY2SMN1; SMN2 | |
| SCHEMBL7803298 | 0.84 | ADORA1 (0.76) | AHCYP2RY1ADORA1P2RY2SMN1; SMN2 | |
| SCHEMBL2040670 | 0.84 | ADORA1 (0.76) | AHCYP2RY1ADORA1P2RY2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060246438-A1 | Methods for the chemical and physical modification of nanotubes, methods for linking the nanotubes, methods for the directed positioning of nanotubes, and uses thereof | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2006-11-02 | — | — | US | claimed |
| EP-1549662-A1 | METHODS FOR THE CHEMICAL AND PHYSICAL MODIFICATION OF NANOTUBES, METHODS FOR LINKING THE NANOTUBES, METHODS FOR THE DIRECTED POSITIONING OF NANOTUBES, AND USES THEREOF | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2005-07-06 | — | — | EP | claimed |
| EP-1017725-A4 | METHOD OF AFFINITY CROSS-LINKING BIOLOGICALLY ACTIVE, IMMUNOGENIC PEPTIDES TO ANTIBODIES | INNEXUS BIOTECHNOLOGY INTERNAT (CA) | 2004-06-30 | — | — | EP | claimed |
| WO-2004020450-A1 | METHODS FOR THE CHEMICAL AND PHYSICAL MODIFICATION OF NANOTUBES, METHODS FOR LINKING THE NANOTUBES, METHODS FOR THE DIRECTED POSITIONING OF NANOTUBES, AND USES THEREOF | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-03-11 | — | — | WO | claimed |
| EP-1017725-A1 | METHOD OF AFFINITY CROSS-LINKING BIOLOGICALLY ACTIVE, IMMUNOGENIC PEPTIDES TO ANTIBODIES | Immpheron Incorporated (US) | 2000-07-12 | — | — | EP | claimed |
| WO-1999014244-A1 | METHOD OF AFFINITY CROSS-LINKING BIOLOGICALLY ACTIVE, IMMUNOGENIC PEPTIDES TO ANTIBODIES | KOHLER HEINZ (US) | 1999-03-25 | — | — | WO | claimed |
| EP-4748838-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4658664-A1 | CAP ANALOGS WITH 5'-TERMINAL ACYCLIC GUANOSINE DERIVATIVE | CureVac SE (DE) | 2025-12-10 | — | — | EP | disclosed |
| EP-4045498-B1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | UNIV CALIFORNIA (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4466074-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | The Broad Institute Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024160895-A1 | CAP ANALOGS WITH 5'-TERMINAL ACYCLIC GUANOSINE DERIVATIVE | CureVac SE (DE) | 2024-08-08 | — | — | WO | disclosed |
| WO-2023007019-A9 | CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE | CureVac SE (DE) | 2024-02-29 | — | — | WO | disclosed |
| WO-1996013522-A9 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | — | 1996-09-12 | — | — | WO | disclosed |
| WO-1996013522-A1 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | BURSTEIN LABORATORIES, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0165313-B1 | NUCLEIC ACID HYBRIDIZATION ASSAY | HRI RESEARCH, INC. (US) | 1989-11-15 | — | — | EP | disclosed |
| US-4599303-A | PSORALEN DERIVATIVES | HRI ASSOCIATES, INC. (US) | 1986-07-08 | — | — | US | disclosed |
| EP-0165313-A4 | NUCLEIC ACID HYBRIDIZATION ASSAY. | HRI RES INC (US) | 1986-05-16 | — | — | EP | disclosed |
| EP-0165313-A1 | NUCLEIC ACID HYBRIDIZATION ASSAY. | HYDROCARBON RESEARCH INC (US) | 1985-12-27 | — | — | EP | disclosed |
| WO-1985002628-A1 | NUCLEIC ACID HYBRIDIZATION ASSAY | HRI RESEARCH, INC. (US) | 1985-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630527-B2 | Broad spectrum anti-cancer compounds | YTHDF3, YTHDF1, YTHDF2 | AHCY 917/4885P2RY1 4435/4885ADORA1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.